Mimma Rizzo
YOU?
Author Swipe
View article: Impact of neoadjuvant chemotherapy dose intensity on pathological response and survival in muscle-invasive urothelial carcinoma
Impact of neoadjuvant chemotherapy dose intensity on pathological response and survival in muscle-invasive urothelial carcinoma Open
View article: Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients
Longitudinal validation of the PROFFIT questionnaire to assess financial toxicity in cancer patients Open
PROFFIT validation analyses make the instrument suitable to measure FT in cancer patients within public health systems. In addition, it may represent a valuable tool to plan specific local health policies being sensible to macro-regional v…
View article: IUC24403-78 Relative dose intensity of neoadjuvant chemotherapy predicts pathological response and survival in muscle-invasive urothelial cancer: a multicenter retrospective study
IUC24403-78 Relative dose intensity of neoadjuvant chemotherapy predicts pathological response and survival in muscle-invasive urothelial cancer: a multicenter retrospective study Open
Background The relative dose intensity (RDI) of neoadjuvant chemotherapy (NAC) is known to influence pathological response and survival in several solid tumors. However, its role in muscle-invasive urothelial carcinoma (MIUC) remains under…
View article: Assessing Effective Engagement with Digital Behavior Change Intervention: The Case Study of the CAPABLE Project
Assessing Effective Engagement with Digital Behavior Change Intervention: The Case Study of the CAPABLE Project Open
Digital Behavior Change Interventions (DBCIs) can support the development of new health behaviors. Evaluating their effectiveness is crucial for improving them and understanding the factors that contribute to their success. Building on the…
View article: mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1α)
mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1α) Open
View article: Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study.
Geographical Differences in the Management and Outcomes of Patients With Advanced Urothelial Carcinoma Treated With Pembrolizumab After Progression on Platinum-Based Chemotherapy: Results From ARON-2 Study. Open
Real-world data suggest that facilitating and extending access to targeted therapies for patients with aUC in different geographical areas worldwide may lead to a consistent and widespread survival increase.
View article: Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study
Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study Open
View article: Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab Open
Gender- and sex-based disparities in response to immune-checkpoint inhibitors (ICI) has been reported in a variety of tumor types. Women have different anatomy with recurrent urinary tract infections, a different sex hormonal profile, and …
View article: Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy
Prognostic Value of G8 Geriatric Screening and Meet-URO Scores in Metastatic Renal Cell Carcinoma Patients Receiving First-Line Ipilimumab-Nivolumab Combination Immunotherapy Open
Background The prognostic value of the Geriatric 8 (G8) screening score in metastatic renal cell carcinoma (mRCC) patients receiving first-line immunotherapy remains unclear. This study aimed to evaluate the prognostic role of G8 within th…
View article: Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The <scp>ARON</scp>‐2 Retrospective Experience
Real‐Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The <span>ARON</span>‐2 Retrospective Experience Open
Background Recently, a plethora of novel systemic agents have been incorporated into the therapeutic armamentarium of advanced urothelial carcinoma (aUC). The antibody–drug conjugate (ADC), enfortumab vedotin (EV), has demonstrated relevan…
View article: Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study
Apalutamide in Metastatic Castration-sensitive Prostate Cancer: Results from the Multicenter Real-world ARON-3 Study Open
View article: Exploring the Impact of the Multimodal CAPABLE eHealth Intervention on Health-Related Quality of Life in Patients With Melanoma Undergoing Immune-Checkpoint Inhibition: Prospective Pilot Study
Exploring the Impact of the Multimodal CAPABLE eHealth Intervention on Health-Related Quality of Life in Patients With Melanoma Undergoing Immune-Checkpoint Inhibition: Prospective Pilot Study Open
Background Patients with melanoma receiving immunotherapy with immune-checkpoint inhibitors often experience immune-related adverse events, cancer-related fatigue, and emotional distress, affecting health-related quality of life () and cli…
View article: Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study
Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study Open
View article: Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study)
Clinical features and response to immune combinations in patients with renal cell carcinoma and sarcomatoid de‐differentiation (ARON‐1 study) Open
Metastatic renal cell carcinoma (mRCC) carrying sarcomatoid features (sRCC) has aggressive biology and poor prognosis. First‐line immunotherapy (IO)‐based combinations have improved the outcome of clear cell RCC patients, including that of…
View article: Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study Open
View article: A novel interface terminology for patient-reported outcomes in home patients monitoring applications. (Preprint)
A novel interface terminology for patient-reported outcomes in home patients monitoring applications. (Preprint) Open
The results obtained from the clinical study support our claim regarding the need for a novel terminology for the self-reporting of AEs, characterized by ease of use, completeness, and clinical meaningfulness. Finally, by mapping our termi…
View article: Clinical outcome predictors for metastatic renal cell carcinoma: a retrospective multicenter real-life case series
Clinical outcome predictors for metastatic renal cell carcinoma: a retrospective multicenter real-life case series Open
View article: Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25) Open
NER
View article: Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study Open
View article: Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma
Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma Open
The clinical management of metastatic urothelial carcinoma (mUC) is undergoing a major paradigm shift; the integration of immune checkpoint inhibitors (ICIs) and antibody–drug conjugates (ADCs) into the mUC therapeutic strategy has succeed…
View article: Defining Effective Engagement For Enhancing Cancer Patients' Well-being with Mobile Digital Behavior Change Interventions
Defining Effective Engagement For Enhancing Cancer Patients' Well-being with Mobile Digital Behavior Change Interventions Open
Digital Behavior Change Interventions (DBCIs) are supporting development of new health behaviors. Evaluating their effectiveness is crucial for their improvement and understanding of success factors. However, comprehensive guidance for dev…
View article: Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients
Assessing the effectiveness and safety of lenvatinib and everolimus in advanced renal cell carcinoma: insights from the RELIEVE study’s analysis of heavily pretreated patients Open
Background: The treatment of heavily pretreated patients with metastatic renal cell carcinoma (mRCC) represents an unmet medical need and is still challenging. Objectives: The primary objective was to assess the effectiveness of the lenvat…
View article: Genomic profiling and molecular characterization of non-clear cell renal cell carcinoma: a narrative review from a clinical perspective
Genomic profiling and molecular characterization of non-clear cell renal cell carcinoma: a narrative review from a clinical perspective Open
While the clear-cell renal cell carcinoma (ccRCC) treatment has undergone several paradigm shifts in recent years, the non-clear cell renal cell carcinoma (nccRCC) therapeutic approach has yet to be extensively investigated and improved. T…
View article: Concomitant Immunotherapy and Metastasis-Directed Radiotherapy in Upper Tract Urothelial Carcinoma: A Biomarker-Driven, Original, Case-Based Proof-of-Concept Study
Concomitant Immunotherapy and Metastasis-Directed Radiotherapy in Upper Tract Urothelial Carcinoma: A Biomarker-Driven, Original, Case-Based Proof-of-Concept Study Open
Metastatic upper tract urothelial carcinoma (mUTUC) has a poor prognosis. Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in patients with metastatic urothelial carcinoma. However, data supporting the use of ICIs in patients…
View article: Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients
Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients Open
View article: mTOR eosinophilic renal cell carcinoma: a distinctive tumor characterized by mTOR mutation, loss of chromosome 1, cathepsin-K expression, and response to target therapy
mTOR eosinophilic renal cell carcinoma: a distinctive tumor characterized by mTOR mutation, loss of chromosome 1, cathepsin-K expression, and response to target therapy Open
View article: Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study Open
View article: Genomic Profiling and Molecular Characterization of Clear Cell Renal Cell Carcinoma
Genomic Profiling and Molecular Characterization of Clear Cell Renal Cell Carcinoma Open
Clear cell renal cell carcinoma (ccRCC) treatment has undergone three major paradigm shifts in recent years, first with the introduction of molecular targeted therapies, then with immune checkpoint inhibitors, and, more recently, with immu…
View article: Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis Open
View article: Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study Open